ArticleEJHaem2025
Multiple Myeloma in Young Adults-Insights From a Tertiary Care Cancer Centre in India.
Article in EJHaem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiple myeloma (MM) is primarily a disease of the elderly; data on young patients are limited. Aim: To evaluate the clinical characteristics and outcomes of MM patients aged Methods: We retrospectively analyzed newly diagnosed MM patients aged ≤ 40 years between 2013 and 2021. Results: Of 1980 patients screened, 110 (5.5%) were ≤ 40 years (median age 36). Hypercalcemia, renal dysfunction, anemia, and bone lesions (CRAB) were seen in 11.9%, 17.3%, 42.7%, and 92.6% of patients, respectively. More than one-third had International Staging System (ISS) Stage III, 20.8% had HR cytogenetics and 21.6% had light chain disease (LCD). Macrofocal multiple myeloma (MFMM) seen in 31% of patients. Bortezomib-cyclophosphamide-dexamethasone (VCd) and bortezomib-lenalidomide-dexamethasone (VRd) were the common induction regimens. 26.8% received autologous stem cell transplantation (ASCT). At a median follow-up of 44.2 months, the median progression free survival (mPFS) was 45.9 months. 1-, 3-, and 5-year PFS rates were 84.9%, 62.2%, and 38.6% respectively. A 3-year PFS was 83.9% with proteasome inhibitor (PI) and 78.7% with immunomodulatory drug (IMiD) as maintenance therapy. A 5-year PFS was superior with ASCT (58.5%) versus without (27.8%). Poor PFS was associated with anemia, renal dysfunction, poor performance status, high risk cytogenetics, VCd (vs. VRd), poor response to induction chemotherapy, no maintenance therapy and no ASCT. Conclusion: Young MM patients had encouraging survival outcomes despite resource limitations and limited access to novel agents. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.